Literature DB >> 25582787

Submyeloablative conditioning with busulfan permits bone marrow-derived cell accumulation in a murine model of Alzheimer's disease.

Christine M Barr1, John Manning1, Coral Ann B Lewis2, Fabio M V Rossi2, Charles Krieger3.   

Abstract

Previous work has suggested that bone marrow (BM)-derived cells (BMDCs) accumulate within the CNS and could potentially associate with β-amyloid plaques in Alzheimer's disease (AD). To explore the accumulation of BMDCs in murine AD, we transplanted green fluorescent protein (GFP)-labeled BM cells into triple transgenic (3×Tg) and wild-type (wt) mice using non-irradiative myelosuppresive conditioning with busulfan (BU). We find that BU (80mg/kg) is sufficient to obtain adequate chimerism (>85%) in wt mice. In order to obtain appreciable non-irradiative chimerism in the 3×Tg mice (>80%), anti-asialo ganglio-N-tetraosylceramide (α-ASGM-1) antibody was also used to reduce natural killer cell function and thereby abrogate the hybrid resistance of the 3×Tg mouse strain. Using BU conditioning and α-ASGM-1 together, we observed sustained BM chimerism and BMDC accumulation within the CNS of the 3×Tg and wt mice. In cortex and hippocampus, BMDC accumulation was perivascular in distribution and similar between 3×Tg and wt mice, with no clear association between BMDCs and AD plaques. We conclude that non-irradiative BM chimerism can be achieved with BU in 3×Tg mice, but requires α-ASGM-1 (or similar appropriate NK-cell depletion). Use of this chimerism protocol permits BMDCs accumulation in the CNS of mixed strain recipient mice although BMDCs appear to be largely perivascular within cortex and hippocampus.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  3×Tg mice; Bone marrow-derived cells; Busulfan; Busulfex; Chimerism; Hybrid resistance

Mesh:

Substances:

Year:  2015        PMID: 25582787     DOI: 10.1016/j.neulet.2015.01.023

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Origin, fate and dynamics of macrophages at central nervous system interfaces.

Authors:  Tobias Goldmann; Peter Wieghofer; Marta Joana Costa Jordão; Fabiola Prutek; Nora Hagemeyer; Kathrin Frenzel; Lukas Amann; Ori Staszewski; Katrin Kierdorf; Martin Krueger; Giuseppe Locatelli; Hannah Hochgerner; Robert Zeiser; Slava Epelman; Frederic Geissmann; Josef Priller; Fabio M V Rossi; Ingo Bechmann; Martin Kerschensteiner; Sten Linnarsson; Steffen Jung; Marco Prinz
Journal:  Nat Immunol       Date:  2016-05-02       Impact factor: 25.606

2.  Bone Marrow-Derived Cell Accumulation in the Spinal Cord Is Independent of Peripheral Mobilization in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Kyle Peake; John Manning; Coral-Ann Lewis; Kevin Tran; Fabio Rossi; Charles Krieger
Journal:  Front Neurol       Date:  2017-03-08       Impact factor: 4.003

3.  Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model.

Authors:  Nahee Park; Kamal Pandey; Sei Kyung Chang; Ah-Young Kwon; Young Bin Cho; Jin Hur; Nar Bahadur Katwal; Seung Ki Kim; Seung Ah Lee; Gun Woo Son; Jong Min Jo; Hee Jung Ahn; Yong Wha Moon
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

Review 4.  Concepts of Neuroinflammation and Their Relationship With Impaired Mitochondrial Functions in Bipolar Disorder.

Authors:  Luiz Arthur Rangel Cyrino; Daniela Delwing-de Lima; Oliver Matheus Ullmann; Thayná Patachini Maia
Journal:  Front Behav Neurosci       Date:  2021-02-26       Impact factor: 3.558

Review 5.  The Pivotal Immunoregulatory Functions of Microglia and Macrophages in Glioma Pathogenesis and Therapy.

Authors:  Seidu A Richard
Journal:  J Oncol       Date:  2022-04-04       Impact factor: 4.375

Review 6.  Microglia at center stage: a comprehensive review about the versatile and unique residential macrophages of the central nervous system.

Authors:  Nils Lannes; Elisabeth Eppler; Samar Etemad; Peter Yotovski; Luis Filgueira
Journal:  Oncotarget       Date:  2017-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.